Jefferies expects healthy iDose uptake to support sales growth acceleration in 25E/26E, along with stability in the base ...

Q1 2024 Earnings Call Transcript May 5, 2024 Sight Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, ...

MIAMI, FL — Fifteen Bascom Palmer Eye Institute physicians were selected for the 2024 Power List, a selection of the world’s ...

The anticipated near-term sales growth inflection for iDose, combined with the sustained performance of Glaukos’s core glaucoma and corneal health franchises, underpins the upgrade to a Buy rating.

(increased pressure in the eye), uveitis (inflammation of the uvea), squinting or blinking (indicative of eye discomfort or ...

Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and ...